AxoGen (AXGN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.21
- Estimate
- $0.13
- Surprise
- +59.9%
- Revenue (period 2026-09-30)
- $75.8M
- Score at report (before → after)
- 5.8 → 5.6/10
Revenue source: xbrl.
How the report landed
AxoGen (AXGN) beat the $0.13 estimate with adjusted EPS of $0.21 — a large 59.9% upside surprise. TrendMatrix's engine moved from Sell (5.8/10) to Hold at 5.6/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AXGN Sell at 5.4/10.
1 of the last 4 quarters beat the estimate; this quarter's +59.9% surprise compares with a +7.8% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- Strong growth profile
What argues against it
- Analyst target reached - limited upside remaining
- Expensive valuation
- Target reached (-7.5% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $55.72
- Stop
- $51.82
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
AXGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $3.31B
- P/E (fwd)
- 78.5
- 52-week range
- $23.00–$59.72
- Off 52-week high
- 6.7%
- RSI (14)
- 66
- Volume vs avg
- 0.35×
- Score today
- 5.4/10